Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantSV
SoftBank Vision Fund 2
Activity from announced rounds
Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026
SoftBank Vision Fund 2 is the specified fund explicitly named by Zenity and Encoded.
Recorded funding activity
Zenity secures enterprise agents. Encoded develops neurological gene therapies, while Emergent develops AI software-creation tools. The vehicle remains distinct from Vision Fund 1, SoftBank itself and fund advisers.
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 3 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $935M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionZenity
AI security and governance platform purpose-built for enterprise AI agents
$125MSeries C
Role not disclosedHelion
Develops magneto-inertial fusion power technology to generate electricity for commercial deployment
$465MSeries G
Role not disclosedEmergent
Provides AI software creation platform for building full-stack web and mobile applications
$70MSeries B
Role not disclosed